PGEN
Precigen is a commercial-stage biopharmaceutical company developing precision medicines in immuno-oncology, autoimmune disorders, and infectious diseases using its AdenoVerse immunotherapy and UltraCAR-T cell therapy platforms, which employ adenoviral vectors and electroporation-based manufacturing via its proprietary UltraPorator device. The company achieved FDA approval in August 2025 for Papzimeos (zopapogene imadenovec-drba), a non-replicating adenoviral vector immunotherapy for recurrent respiratory papillomatosis, and maintains a clinical pipeline including PRGN-2009 in Phase 2 development for HPV-associated cancers under a National Cancer Institute collaboration and PRGN-3006, a UltraCAR-T candidate with completed Phase 1b enrollment. Precigen employs disciplined portfolio management to advance programs